Press Releases

MinervaX announces investment of 4.4 mEUR

MinervaX announces award of 4.4 million euro in investment from Novo Holding's repair impact fund and Sunstone Life Science Ventures for further clinical development of the company's vaccine against...

read more

Initiation of Phase I clinical trial

MinervaX initiates phase I clinical trial with innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns. Novel, single component vaccine predicted to protect...

read more

Equity and Loan Financing

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. MinervaX, a privately held Danish biotech company,...

read more

FP7 Grant

Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns secures funding to reach clinical proof of concept. NeoStrep, a consortium consisting of Lund University...

read more

Eurostar Grant

MinervaX announces the award of a Eurostars Grant in collaboration with Bioneer (Denmark), The Danish Technical University (Denmark) and Telormedix (Switzerland) for the development of a LIPODEL...

read more

Technology Foundation Grant

MinervaX Announces the award of a grant from The Danish National Advanced Technology Foundation together with The State Serum Institute and University of Copenhagen for the development and testing...

read more

Danish Government Grant

MinervaX Announces the award of a 500,000 DKK (66,000 EUR) grant from the Ministry of Science, Technology and Innovation — “Videnkupon”. MinervaX, a private biotech company developing a novel...

read more
Press Release

Categories